IRX2

Across TCGA pan-cancer cohorts, IRX2 mass-spec protein differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of IRX2’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where IRX2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types IRX2 is over-expressed in tumor, although a few such as LSCC and LUAD show the opposite, repressed pattern.

LSCC and LUAD are the cancer types where IRX2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in IRX2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	All	All	−0.690	<.001	8	view →
LUAD	Male	All	−0.363	<.001	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 2 strongest of 2 lineages.

IRX2–LSCC

Open the LSCC breakdown →